Study on Mirdametinib for Treating Central Nervous System Tumors

Exclusion Criteria

• Pregnant or nursing women cannot participate.
• Participants cannot be involved in another treatment study at the same time, although joining non-treatment registries is allowed.
• Cannot have received any tumor-targeting treatments like chemotherapy or experimental drugs within 28 days before starting mirdametinib.
• Cannot use medications that strongly affect liver enzymes (CYP3A).
• Cannot have a history of allergic reactions to mirdametinib or similar drugs.
• Must not have serious active infections; participants must be fever-free for at least 48 hours.
• Cannot have uncontrolled or severe medical conditions.
• Cannot have significant heart disease within 6 months before starting treatment, including severe heart failure or recent heart attacks.
• Cannot have significant eye diseases within 6 months before starting treatment, like central retinal vein occlusion.
• Cannot have any condition or treatment that might interfere with the study results or participation.
• For Cohort A: Patients with specific genetic mutations outside the MAPK pathway are not eligible.

On Study Guidelines:

• Patients with blood, kidney, or liver issues due to their disease may join if the investigator believes mirdametinib could help.
• For Cohort A: No prior therapy is required due to the limited effectiveness of standard treatments for CNS tumors and neurohistiocytosis.
• Female participants who can become pregnant must use effective birth control during the study and for 6 weeks after. Male participants with partners who can become pregnant must use birth control during the study and for 3 months after. If a participant becomes pregnant or suspects pregnancy, they should inform their doctor immediately.